Neuropace Stock Based Compensation vs Change To Inventory Analysis

NPCE Stock

USD 8.42 0.14 1.64%

Neuropace financial indicator trend analysis is infinitely more than just investigating Neuropace recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neuropace is a good investment. Please check the relationship between Neuropace Stock Based Compensation and its Change To Inventory accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in banks.

For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.

Stock Based Compensation vs Change To Inventory

Stock Based Compensation vs Change To Inventory Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neuropace Stock Based Compensation account and Change To Inventory. At this time, the significance of the direction appears to have very week relationship.

The correlation between Neuropace's Stock Based Compensation and Change To Inventory is 0.28. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Change To Inventory in the same time period over historical financial statements of Neuropace, assuming nothing else is changed. The correlation between historical values of Neuropace's Stock Based Compensation and Change To Inventory is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Neuropace are associated (or correlated) with its Change To Inventory. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Inventory has no effect on the direction of Stock Based Compensation i.e., Neuropace's Stock Based Compensation and Change To Inventory go up and down completely randomly.

Correlation Coefficient

0.28

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Change To Inventory

The increase or decrease in the amount of inventory a company has over a certain period.

Most indicators from Neuropace's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neuropace current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in banks.

For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.As of August 18, 2025, Selling General Administrative is expected to decline to about 47.6 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 3.1 M

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	3.0M	1.6M	1.8M	1.4M
Interest Income	1.6M	3.1M	3.0M	1.5M

Depreciation And Amortization Interest Income

Neuropace fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital
Total Assets		0.17	0.89	-0.93	0.98	-0.97	0.96	0.72	-0.93	-0.39	-0.82	0.8	0.7	0.73	0.54	0.53	0.98	0.7	0.93	0.97	-0.13	0.6	0.92	0.97	-0.85	0.95
Short Long Term Debt Total	0.17		0.36	-0.1	0.07	-0.36	0.34	0.75	-0.18	0.73	-0.59	0.66	-0.2	0.74	0.16	-0.59	0.0	0.55	0.45	0.04	-0.38	0.79	0.48	0.37	-0.38	0.29
Other Current Liab	0.89	0.36		-0.87	0.88	-0.9	0.86	0.78	-0.89	-0.31	-0.87	0.83	0.75	0.79	0.67	0.26	0.83	0.87	0.88	0.78	-0.03	0.7	0.86	0.91	-0.72	0.83
Total Current Liabilities	-0.93	-0.1	-0.87		-0.98	0.89	-0.82	-0.68	0.99	0.55	0.8	-0.76	-0.86	-0.7	-0.79	-0.37	-0.91	-0.76	-0.84	-0.85	-0.22	-0.55	-0.81	-0.9	0.62	-0.79
Total Stockholder Equity	0.98	0.07	0.88	-0.98		-0.93	0.89	0.67	-0.97	-0.53	-0.79	0.75	0.81	0.69	0.66	0.5	0.97	0.71	0.88	0.93	0.07	0.54	0.86	0.94	-0.73	0.88
Other Liab	-0.97	-0.36	-0.9	0.89	-0.93		-0.97	-0.83	0.91	0.22	0.88	-0.91	-0.61	-0.83	-0.52	-0.4	-0.92	-0.8	-0.99	-0.91	0.21	-0.77	-0.95	-1.0	0.88	-0.96
Net Tangible Assets	0.96	0.34	0.86	-0.82	0.89	-0.97		0.76	-0.85	-0.17	-0.88	0.86	0.53	0.76	0.37	0.47	0.92	0.71	0.98	0.94	-0.37	0.73	0.94	0.97	-0.95	0.98
Property Plant And Equipment Net	0.72	0.75	0.78	-0.68	0.67	-0.83	0.76		-0.72	0.22	-0.85	0.93	0.32	1.0	0.55	-0.15	0.59	0.79	0.85	0.61	-0.19	0.86	0.9	0.84	-0.7	0.74
Current Deferred Revenue	-0.93	-0.18	-0.89	0.99	-0.97	0.91	-0.85	-0.72		0.49	0.86	-0.81	-0.85	-0.74	-0.79	-0.32	-0.89	-0.81	-0.87	-0.83	-0.19	-0.63	-0.82	-0.92	0.65	-0.8
Net Debt	-0.39	0.73	-0.31	0.55	-0.53	0.22	-0.17	0.22	0.49		0.05	0.07	-0.82	0.19	-0.48	-0.62	-0.5	-0.14	-0.12	-0.39	-0.58	0.27	-0.04	-0.23	-0.03	-0.17
Retained Earnings	-0.82	-0.59	-0.87	0.8	-0.79	0.88	-0.88	-0.85	0.86	0.05		-0.93	-0.57	-0.85	-0.6	-0.07	-0.73	-0.88	-0.91	-0.71	0.15	-0.87	-0.86	-0.91	0.76	-0.79
Accounts Payable	0.8	0.66	0.83	-0.76	0.75	-0.91	0.86	0.93	-0.81	0.07	-0.93		0.46	0.93	0.54	0.04	0.68	0.9	0.94	0.68	-0.2	0.95	0.88	0.92	-0.77	0.82
Cash	0.7	-0.2	0.75	-0.86	0.81	-0.61	0.53	0.32	-0.85	-0.82	-0.57	0.46		0.35	0.82	0.39	0.72	0.66	0.55	0.59	0.52	0.28	0.45	0.64	-0.28	0.48
Non Current Assets Total	0.73	0.74	0.79	-0.7	0.69	-0.83	0.76	1.0	-0.74	0.19	-0.85	0.93	0.35		0.58	-0.14	0.6	0.8	0.85	0.61	-0.16	0.85	0.9	0.84	-0.69	0.74
Non Currrent Assets Other	0.54	0.16	0.67	-0.79	0.66	-0.52	0.37	0.55	-0.79	-0.48	-0.6	0.54	0.82	0.58		-0.15	0.47	0.72	0.46	0.35	0.68	0.41	0.45	0.55	-0.09	0.3
Other Assets	0.53	-0.59	0.26	-0.37	0.5	-0.4	0.47	-0.15	-0.32	-0.62	-0.07	0.04	0.39	-0.14	-0.15		0.65	-0.03	0.35	0.67	-0.25	-0.13	0.27	0.37	-0.5	0.54
Cash And Short Term Investments	0.98	0.0	0.83	-0.91	0.97	-0.92	0.92	0.59	-0.89	-0.5	-0.73	0.68	0.72	0.6	0.47	0.65		0.59	0.87	0.99	-0.11	0.46	0.86	0.92	-0.82	0.92
Net Receivables	0.7	0.55	0.87	-0.76	0.71	-0.8	0.71	0.79	-0.81	-0.14	-0.88	0.9	0.66	0.8	0.72	-0.03	0.59		0.82	0.52	0.07	0.89	0.69	0.81	-0.55	0.64
Common Stock Shares Outstanding	0.93	0.45	0.88	-0.84	0.88	-0.99	0.98	0.85	-0.87	-0.12	-0.91	0.94	0.55	0.85	0.46	0.35	0.87	0.82		0.87	-0.29	0.84	0.94	0.99	-0.91	0.96
Short Term Investments	0.97	0.04	0.78	-0.85	0.93	-0.91	0.94	0.61	-0.83	-0.39	-0.71	0.68	0.59	0.61	0.35	0.67	0.99	0.52	0.87		-0.25	0.47	0.89	0.91	-0.88	0.95
Non Current Liabilities Total	-0.13	-0.38	-0.03	-0.22	0.07	0.21	-0.37	-0.19	-0.19	-0.58	0.15	-0.2	0.52	-0.16	0.68	-0.25	-0.11	0.07	-0.29	-0.25		-0.3	-0.31	-0.18	0.62	-0.41
Inventory	0.6	0.79	0.7	-0.55	0.54	-0.77	0.73	0.86	-0.63	0.27	-0.87	0.95	0.28	0.85	0.41	-0.13	0.46	0.89	0.84	0.47	-0.3		0.73	0.77	-0.68	0.67
Other Current Assets	0.92	0.48	0.86	-0.81	0.86	-0.95	0.94	0.9	-0.82	-0.04	-0.86	0.88	0.45	0.9	0.45	0.27	0.86	0.69	0.94	0.89	-0.31	0.73		0.95	-0.9	0.94
Other Stockholder Equity	0.97	0.37	0.91	-0.9	0.94	-1.0	0.97	0.84	-0.92	-0.23	-0.91	0.92	0.64	0.84	0.55	0.37	0.92	0.81	0.99	0.91	-0.18	0.77	0.95		-0.87	0.95
Total Liab	-0.85	-0.38	-0.72	0.62	-0.73	0.88	-0.95	-0.7	0.65	-0.03	0.76	-0.77	-0.28	-0.69	-0.09	-0.5	-0.82	-0.55	-0.91	-0.88	0.62	-0.68	-0.9	-0.87		-0.96
Net Invested Capital	0.95	0.29	0.83	-0.79	0.88	-0.96	0.98	0.74	-0.8	-0.17	-0.79	0.82	0.48	0.74	0.3	0.54	0.92	0.64	0.96	0.95	-0.41	0.67	0.94	0.95	-0.96

Click cells to compare fundamentals

Neuropace Account Relationship Matchups

Neuropace fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	56.0M	133.6M	114.1M	107.7M	94.6M	96.6M
Short Long Term Debt Total	52.9M	49.8M	69.8M	72.4M	73.3M	69.9M
Other Current Liab	6.6M	7.9M	7.4M	11.2M	7.9M	8.4M
Total Current Liabilities	9.6M	9.3M	11.0M	16.2M	15.2M	18.2M
Total Stockholder Equity	(6.4M)	73.5M	34.8M	20.7M	8.0M	8.4M
Property Plant And Equipment Net	515K	603K	15.9M	14.4M	12.9M	8.3M
Net Debt	26.5M	30.7M	63.2M	54.3M	59.9M	53.8M
Retained Earnings	(387.7M)	(423.8M)	(470.9M)	(503.8M)	(531.0M)	(557.5M)
Accounts Payable	949K	1.4M	2.1M	2.3M	3.0M	2.0M
Cash	26.4M	19.2M	6.6M	18.1M	13.4M	16.1M
Non Current Assets Total	1.4M	746K	16.4M	14.9M	13.3M	8.7M
Non Currrent Assets Other	873K	21K	368K	524K	413K	407.7K
Cash And Short Term Investments	38.1M	115.6M	77.4M	66.5M	52.8M	65.2M
Net Receivables	8.4M	7.1M	7.5M	12.3M	12.9M	9.9M
Short Term Investments	11.7M	96.4M	70.8M	48.4M	39.3M	49.1M
Liabilities And Stockholders Equity	56.0M	133.6M	114.1M	107.7M	94.6M	96.6M
Non Current Liabilities Total	194.2M	50.8M	68.4M	70.8M	71.5M	70.8M
Inventory	6.9M	7.8M	9.7M	11.2M	13.4M	10.4M
Other Current Assets	1.2M	2.3M	3.1M	2.7M	2.4M	2.4M
Other Stockholder Equity	239.8M	497.5M	506.7M	524.4M	538.9M	452.5M
Total Liab	203.8M	60.1M	79.3M	87.0M	86.6M	89.0M
Net Invested Capital	(95.0M)	123.4M	87.7M	77.6M	67.5M	35.7M
Property Plant And Equipment Gross	515K	603K	1.1M	22.2M	20.9M	21.9M
Total Current Assets	54.6M	132.8M	97.7M	92.7M	81.3M	87.9M
Net Working Capital	45.0M	123.5M	86.7M	76.5M	66.2M	62.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

HLN	Haleon plc
NVDA	NVIDIA
INTC	Intel

When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:

How To Invest In Neuropace

Details

Is Neuropace Stock a good investment?

Details

What is Neuropace's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in banks.

For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.82)

Revenue Per Share

2.864

Quarterly Revenue Growth

0.221

Return On Assets

(0.12)

Return On Equity

(1.77)

The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Neuropace Stock Based Compensation vs Change To Inventory Analysis

Stock Based Compensation vs Change To Inventory

Stock Based Compensation vs Change To Inventory Correlation Analysis

Correlation Coefficient

Stock Based Compensation

Change To Inventory

Neuropace fundamental ratios Correlations

Neuropace Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neuropace fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Current Deferred Revenue	+ 0.99	Total Current Liabilities
Short Term Investments	+ 0.99	Cash And Short Term Investments
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Total Stockholder Equity	+ 0.98	Total Assets
Cash And Short Term Investments	+ 0.98	Total Assets

Other Stockholder Equity	- 1.0	Other Liab
Common Stock Shares Outstanding	- 0.99	Other Liab
Total Stockholder Equity	- 0.98	Total Current Liabilities
Net Tangible Assets	- 0.97	Other Liab
Current Deferred Revenue	- 0.97	Total Stockholder Equity
Other Liab	- 0.97	Total Assets